From Tumor Sequencing to “One Patient, One Drug”: Machine-Learning-Assisted Design of V940 Individualized Neoantigen mRNA and the Phase III Breakthrough in Melanoma
On August 19, 2026, Merck and Moderna announced positive topline results from a Phase III clinical trial in melanoma. The study evaluated a patient-specific messenger RNA (mRNA) neoantigen therapy in combination with pembrolizumab. The therapy was previously designated mRNA-4157/V940 during ...
危险品化学品经营许可证（带存储）